Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 10 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9222091

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Dec 29, 2015 · Expires Dec 24, 2035

    granted
  2. US 9212364

    Compositions and methods for inhibiting expression of mutant EGFR gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 15, 2015 · Expires Dec 10, 2035

    granted
  3. US 9206421

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 8, 2015 · Expires Dec 3, 2035

    granted
  4. US 9198972

    Monomers and oligonucleotides comprising cycloaddition adduct(s)

    Alnylam Pharmaceuticals, Inc. · Granted Dec 1, 2015 · Expires Nov 26, 2035

    granted
  5. US 9200281

    Conserved HBV and HCV sequences useful for gene silencing

    Alnylam Pharmaceuticals, Inc. · Granted Dec 1, 2015 · Expires Nov 26, 2035

    granted
  6. US 9200282

    Compositions and methods for inhibiting expression of an RNA from west nile virus

    Alnylam Pharmaceuticals, Inc. · Granted Dec 1, 2015 · Expires Nov 26, 2035

    granted
  7. US 9198983

    Compositions and methods for inhibiting expression of Mylip/Idol gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 1, 2015 · Expires Nov 26, 2035

    granted
  8. US 9198927

    Targeting opposite strand replication intermediates of single-stranded viruses by RNAI

    Alnylam Pharmaceuticals, Inc. · Granted Dec 1, 2015 · Expires Nov 26, 2035

    granted
  9. US 9187746

    Dual targeting siRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Nov 17, 2015 · Expires Nov 12, 2035

    granted
  10. US 9187747

    RNAi modulation of ApoB and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 17, 2015 · Expires Nov 12, 2035

    granted
  11. US 9175290

    Compositions and methods for inhibiting expression of TMPRSS6 gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 3, 2015 · Expires Oct 29, 2035

    granted
  12. US 9133461

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 15, 2015 · Expires Sep 10, 2035

    granted
  13. US 9133454

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 15, 2015 · Expires Sep 10, 2035

    granted
  14. US 9127277

    Methods and compositions for prevention or treatment of RSV infection

    Alnylam Pharmaceuticals, Inc. · Granted Sep 8, 2015 · Expires Sep 3, 2035

    granted
  15. US 9127274

    Serpinc1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 8, 2015 · Expires Sep 3, 2035

    granted
  16. US 9102938

    2′ and 5′ modified monomers and oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  17. US 9101643

    Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)

    Alnylam Pharmaceuticals, Inc. · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  18. US 9090895

    Compositions and methods for inhibiting expression of the HAMP gene

    Alnylam Pharmaceuticals, Inc. · Granted Jul 28, 2015 · Expires Jul 23, 2035

    granted
  19. US 9074213

    Compositions and methods for inhibiting expression of a target gene

    Alnylam Pharmaceuticals, Inc. · Granted Jul 7, 2015 · Expires Jul 2, 2035

    granted
  20. US 9061063

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Jun 23, 2015 · Expires Jun 18, 2035

    granted
  21. US 9062310

    Compositions and methods for inhibiting expression of factor VII gene

    Alnylam Pharmaceuticals, Inc. · Granted Jun 23, 2015 · Expires Jun 18, 2035

    granted
  22. US 9057069

    Compositions and methods for inhibiting expression of Eg5 gene

    Alnylam Pharmaceuticals, Inc. · Granted Jun 16, 2015 · Expires Jun 11, 2035

    granted
  23. US 9035041

    Process for triphosphate oligonucleotide synthesis

    Alnylam Pharmaceuticals, Inc. · Granted May 19, 2015 · Expires May 14, 2035

    granted
  24. US 9029338

    Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus

    Alnylam Pharmaceuticals, Inc. · Granted May 12, 2015 · Expires May 7, 2035

    granted